by Ian Cooper
The US FDA is preparing to roll out a generative AI model to help with scientific reviews across the agency. Plus, according to US FDA Commissioner Marty Makary the tool will be deployed across the agency by the end of June.
We also have to consider that AI in healthcare was valued at about $26.69 billion in 2024, and at about $39.96 billion in 2025. By 2034, it’s expected to be valued at about $613.81 billion, according to Precedence Research.
As also noted by Precedence Research:
With the ability to process and analyze massive amounts of data, AI is revolutionizing patient care, clinical trials, drug discovery, and administrative tasks. From diagnostic tools to personalized treatments, AI technology is helping healthcare professionals make more informed decisions faster.
In addition, by using artificial intelligence, the company can help accelerate drug discovery, shorten the development process, reduce costs and identify more effective treatments.
That should have a positive impact on stocks like Recursion Pharmaceuticals (RXRX).
Most recently, RXRX achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseases, as noted in its earnings release.
“Our portfolio evolution reflects Recursion’s commitment to advancing medicines in areas of high unmet need where we believe we can have the greatest impact,” said Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion. “As part of our business combination with Exscientia, we are proactively streamlining our portfolio, platform, and operations, making deliberate tradeoffs to focus resources on programs with the strongest scientific rationale and the highest potential for near- and long-term impact.
It should also have a substantial impact on Schrodinger (SDGR).
At the moment, SDGR is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design.
The company’s software allows researchers to design, model, and predict the properties of molecules in silico, or by using computer software. Some of its key products include Maestro (modeling environment), LiveDesign (molecular design), FEP+ (predicts binding affinity of ligands to protein targets), and Glide (high-throughput virtual screening) to name a few.
Recent Comments